However, the treatment of primary open-angle glaucoma (POAG), a multifactorial optic neuropathy linked to progressive retinal ganglion cell death and visual field loss, is one of the primary uses of CA II inhibitors [42,43,44,45,46,47]. Here, CA2 is linked to open-angle glaucoma.